RECURRENT CUTANEOUS MELANOMA
Clinical trials for RECURRENT CUTANEOUS MELANOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CUTANEOUS MELANOMA trials appear
Sign up with your email to follow new studies for RECURRENT CUTANEOUS MELANOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough melanoma: ibrutinib shows promise in early trial
Disease control OngoingThis study tested a drug called ibrutinib in 18 people with stage IV melanoma that had not responded to previous treatments. The goal was to see if the drug could shrink tumors and to study biological markers linked to response or resistance. Ibrutinib works by blocking certain e…
Matched conditions: RECURRENT CUTANEOUS MELANOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:07 UTC
-
New combo therapy shows promise in shrinking melanoma before surgery
Disease control OngoingThis study tests whether adding an experimental drug (CMP-001) to the immunotherapy pembrolizumab can better shrink melanoma tumors before surgery and help prevent the cancer from coming back. About 60 adults with stage III or recurrent melanoma that can be surgically removed wil…
Matched conditions: RECURRENT CUTANEOUS MELANOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:00 UTC
-
New immunotherapy shows promise in preventing melanoma return
Disease control OngoingThis phase 3 trial tests whether the immunotherapy drug pembrolizumab is better than current standard treatments (high-dose interferon or ipilimumab) at preventing melanoma from coming back after surgery. About 1,300 patients with high-risk stage III or IV melanoma that was compl…
Matched conditions: RECURRENT CUTANEOUS MELANOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC